Physician profile
Scott L Mighell
NPI 1093759854
$10,442.33
in general payments reported to CMS, 2019-2025
35 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,888 · 2020: $857 · 2021: $1,032 · 2022: $1,279 · 2023: $1,438 · 2024: $1,577 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,385.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,823.04 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,485.04 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,177.92 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $933.27 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $724.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $648.00 | 2019-2022 | |
| Pfizer INC. | $647.37 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $327.23 | 2021 | |
| Astellas Pharma US INC | $310.21 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.01 | 2019-2025 | Jardiance |
| Allergan, INC. | $271.83 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $195.38 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $177.79 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $163.42 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $160.82 | 2019-2025 | Steglatro, Belsomra, Verquvo |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Mighell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.